Outcomes at 7 years post-transplant in black vs nonblack kidney transplant recipients administered belatacept or cyclosporine in BENEFIT and BENEFIT-EXT. [electronic resource]
Producer: 20190812Description: e13225 p. digitalISSN:- 1399-0012
- Abatacept -- administration & dosage
- Black or African American -- statistics & numerical data
- Cyclosporine -- administration & dosage
- Ethnicity -- statistics & numerical data
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
- Graft Rejection -- drug therapy
- Graft Survival -- drug effects
- Humans
- Immunosuppressive Agents -- administration & dosage
- Incidence
- Kidney Failure, Chronic -- surgery
- Kidney Function Tests
- Kidney Transplantation -- methods
- Male
- Middle Aged
- Postoperative Complications
- Prognosis
- Risk Factors
- Survival Rate
- Time Factors
- Transplant Recipients -- statistics & numerical data
No physical items for this record
Publication Type: Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.